1,3-␤-D-Glucan is a major structural polymer of yeast and fungal cell walls and is synthesized from UDP-glucose by the multisubunit enzyme 1,3-␤-D-glucan synthase. Previous work has shown that the FKS1 gene encodes a 215-kDa integral membrane protein (Fks1p) which mediates sensitivity to the echinocandin class of antifungal glucan synthase inhibitors and is a subunit of this enzyme. We have cloned and sequenced FKS2, a homolog of FKS1 encoding a 217-kDa integral membrane protein (Fks2p) which is 88% identical to Fks1p. The residual glucan synthase activity present in strains with deletions of fks1 is (i) immunodepleted by antibodies prepared against FKS2 peptides, demonstrating that Fks2p is also a component of the enzyme, and (ii) more sensitive to the echinocandin L-733,560, explaining the increased sensitivity of fks1 null mutants to this drug. Simultaneous disruption of FKS1 and FKS2 is lethal, suggesting that Fks1p and Fks2p are alternative subunits with essential overlapping function. Analysis of FKS1 and FKS2 expression reveals that transcription of FKS1 is regulated in the cell cycle and predominates during growth on glucose, while FKS2 is expressed in the absence of glucose. FKS2 is essential for sporulation, a process which occurs during nutritional starvation. FKS2 is induced by the addition of Ca 2؉ to the growth medium, and this induction is completely dependent on the Ca 2؉ /calmodulin-dependent phosphoprotein phosphatase calcineurin. We have previously shown that growth of fks1 null mutants is highly sensitive to the calcineurin inhibitors FK506 and cyclosporin A. Expression of FKS2 from the heterologous ADH1 promoter results in FK506-resistant growth. Thus, the sensitivity of fks1 mutants to these drugs can be explained by the calcineurin-dependent transcription of FKS2. Moreover, FKS2 is also highly induced in response to pheromone in a calcineurin-dependent manner, suggesting that FKS2 may also play a role in the remodeling of the cell wall during the mating process.The cell wall of Saccharomyces cerevisiae is essential for the integrity and shape of the cell and is a highly dynamic structure the composition and architecture of which vary widely depending upon the composition of the growth medium and the stage of the cell cycle (41). In addition, when haploid cells encounter pheromone of the opposite mating type, the cells transiently arrest in the G 1 phase of the cell cycle and develop an elongated projection requiring new cell wall synthesis (12). Furthermore, diploid cells which are nutritionally starved undergo meiosis and sporulation, a process requiring the formation of new cell wall around the developing spores (reviewed in reference 42).An important component of each of these cell wall types is the glucose polymer 1,3-␤-D-glucan (10, 38, 41). 1,3-␤-D-Glucan synthase (UDP-glucose:1,3-␤-D-glucan 3-␤-D-glucosyltransferase; EC 2.4.1.34) is a membrane enzyme activated by GTP which has been fractionated into soluble (GTP-binding) and membrane-bound (catalytic) components (39, 53). Members of...

Echinocandins and nikkomycins are antibiotics that inhibit the synthesis of the essential cell wall polysaccharide polymers 1,3-␤-glucan and chitin, respectively. Some 40 echinocandin-resistant Saccharomyces cerevisiae mutants were isolated and assigned to five complementation groups. Four complementation groups contained mutants with 38 recessive mutations. The fifth complementation group comprised mutants with one dominant mutation, etg1-3 (strain MS10), and one semidominant mutation, etg1-4 (strain MS14).

The GNS1 gene product is required for the synthesis of 1,3-␤-glucan in vitro, since mutations in this gene result in exhibit an 80 to 90% reduction in 1,3-␤-glucan synthase specific activity. gns1 mutant strains display a pleiotropic phenotype including resistance to a pneumocandin B 0 analog (L-733,560), slow growth, and mating and sporulation defects. The gns1-1 mutation was genetically mapped to within 1.35 centimorgans from the MAT locus on chromosome III. The wild-type GNS1 gene was isolated by complementing the pneumocandin resistance phenotype of the gns1-1 mutation and by hybridization with a chromosome III-derived sequence being used as a probe. The nucleotide sequence of GNS1 was determined and compared with the homologous region of the chromosome. The genetic and nucleotide sequence analyses revealed that GNS1 and the open reading frame, YCR34 [S. Oliver, Q. van der Aart, M. Agostoni-Carbone, and the Chromosome III Sequencing Group, Nature (London) 357:38-46, 1992], represent identical loci in the genome. Cells deleted for GNS1 are viable but exhibit slow growth as well as the pleiotropic phenotype of the gns1 mutants. The putative protein product is predicted to be an integral membrane protein with five transmembrane helices displaying an exoplasmic orientation for the N terminus and a cytoplasmic orientation for the C terminus. This protein may be a subunit of 1,3-␤-glucan synthase.

No abstract

Sphingosine-1-phosphate (S1P) receptor agonists are novel immunosuppressive agents. The selectivity of S1P 1 against S1P 3 is strongly correlated with lymphocyte sequestration and minimum acute toxicity and bradycardia. This study describes molecular modeling, site-directed mutagenesis, and affinity studies exploring the molecular basis for selectivity between S1P 1 and S1P 3 receptors. Computational models of human S1P 1 and S1P 3 receptors bound with two nonselective agonists or two S1P 1 -selective agonists were developed based on the X-ray crystal structure of bovine rhodopsin. The models predict that S1P 1 Leu276 and S1P 3 Phe263 contribute to the S1P 1 /S1P 3 selectivity of the two S1P 1 -selective agonists.These residues were subjected to site-directed mutagenesis. The wild-type and mutant S1P receptors were expressed in Chinese hamster ovary cells and examined for their abilities to bind to and be activated by agonists in vitro. The results indicate that the mutations have minimal effects on the activities of the two nonselective agonists, although they have dramatic effects on the S1P 1 -selective agonists. These studies provide a fundamental understanding of how these two receptor-selective agonists bind to the S1P 1 and S1P 3 receptors, which should aid development of more selective S1P 1 receptor agonists with immunosuppressive properties and improved safety profiles.